The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire

Table 1

Pretreatment characteristics of the study population of 42 patients with CML.

Variable	no.
Gender, 𝑛. (%)
Male	26
Female	16
Age (yrs) (median range)	40 (16–69)
Time from diagnosis (yr) (median range)	1.5 (0.1–7)
ECOG at diagnosis
0-1	25 (59)
2-3	17 (41)
Hepatomegaly n (%)	15 (36)
Splenomegaly, n (%)
0 cm	4 (10)
1–9 cm bcma	25 (59)
≥10 cm bcm	13 (31)
Peripheral blood (median range)
Hemoglobin level (g/dL)	10.2 (5.7–13.7)
Platelet count (10^9/L)	331.5 (132–1992)
Leukocyte count (10^9/L)	211.7 (50–854)
Basophils in PB (%)	0 (0–6)
Blasts in PB (%)	1.9 (1–8)
Blasts in BM (%)	1 (0–4)
Ph status before therapy, n (%)
Ph1+	25 (59)
Additional chromosomal abnormalities	17 (41)
Sokal score
Low risk. 𝑛. (%)	11 (16.6)
Intermediate risk 𝑛. (%)	16 (44.5)
High risk 𝑛. (%)	15 (38.9)

Cma: centimeters below the costal margin.